Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954438 | 1.00 | MAPT (0.55) | MAPTTSHREPHX2CNR1KDM4E | |
| SCHEMBL951604 | 0.89 | MAPT (0.55) | MAPTTSHREPHX2CNR1KDM4E | |
| SCHEMBL29952444 | 0.87 | TSHR (0.55) | TSHRCNR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29951371 | 0.85 | TSHR (0.57) | TSHRCNR1KDM4EALDH1A1 | |
| SCHEMBL20214134 | 0.83 | KDM4E (0.69) | MAPTTSHRCNR1KDM4ESMN1; SMN2 | |
| SCHEMBL29953598 | 0.83 | KDM4E (0.69) | MAPTTSHRCNR1KDM4ESMN1; SMN2 | |
| SCHEMBL14602602 | 0.82 | CNR1 (0.62) | MAPTTSHREPHX2CNR1KDM4E | |
| SCHEMBL876134 | 0.80 | MAPT (0.58) | MAPTTSHREPHX2CNR1KDM4E | |
| SCHEMBL16379735 | 0.79 | MAPT (0.57) | MAPTTSHREPHX2CNR1KDM4E | |
| SCHEMBL1438540 | 0.79 | MAPT (0.57) | MAPTTSHREPHX2CNR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-9321748-B2 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-26 | — | — | US | disclosed |
| US-20150336942-A1 | Aminopyridine derived compounds as LRRK2 inhibitors | VERNALIS (R&D) LTD. (GB) | 2015-11-26 | — | — | US | disclosed |
| EP-2941425-A1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2015-11-11 | — | — | EP | disclosed |
| EP-2134685-B1 | 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8853209-B2 | 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2014106612-A1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | WO | disclosed |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES | 2011-10-27 | — | — | US | disclosed |
| US-7981888-B2 | 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives | ABBOTT LABORATORIES (US) | 2011-07-19 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009066060-A2 | 4-SUBSTITUTED-6-ISOPROPYL-BENZENE-1,3-DIOL COMPOUNDS AND THEIR USE | TOPOTARGET A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336942-A1 | Aminopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | MAPT 9/4885TSHR 4796/4885EPHX2 4719/4885 |
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MAPT 3064/4885TSHR 4559/4885EPHX2 4726/4885 |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | LRRK2, PARK7, SNCA | MAPT 9/4885TSHR 4797/4885EPHX2 4729/4885 |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MAPT 3064/4885TSHR 4559/4885EPHX2 4726/4885 |
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | MAPT 2079/4885TSHR 3569/4885EPHX2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.